Frontiers in Pharmacology (Feb 2024)

Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats

  • Jiří Pozniak,
  • Pavel Ryšánek,
  • David Smrčka,
  • Petr Kozlík,
  • Tomáš Křížek,
  • Jaroslava Šmardová,
  • Anežka Nováková,
  • Debanjan Das,
  • Daniel Bobek,
  • Mahak Arora,
  • Jiří Hofmann,
  • Tereza Doušová,
  • Martin Šíma,
  • Ondřej Slanař

DOI
https://doi.org/10.3389/fphar.2024.1331637
Journal volume & issue
Vol. 15

Abstract

Read online

Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration.Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport.Results: Mean ± SD ivacaftor oral bioavailability was 18.4 ± 3.2% and 16.2 ± 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 ± 1.61% and 4.35 ± 1.84%, respectively.Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.

Keywords